01—Abstract
Summary
Summary of the 8-K filed August 18, 2026. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. filed a Form 8-K dated August 18, 2026 under Item 5.02 to report the election of a new director.
On August 14, 2026, Dannielle Appelhans was elected to the Board of Directors. She was placed in the class of directors whose terms end at the Company's 2028 annual meeting of stockholders and was not initially assigned to any Board committee. Ms. Appelhans will be compensated under the Company's director compensation program for non-employee directors, as revised from time to time.
The filing states that this program currently consists of cash retainers for Board and committee service, restricted stock and stock option awards. The current components were described in the proxy statement for the 2026 Annual Meeting of Stockholders, held on May 5, 2026.
The filing states there are no arrangements or understandings under which Ms. Appelhans was elected, and no related person transactions between the Company and her. The filing reports no financial results, guidance, or other operational developments.
02—Key points
Key Highlights
- On August 14, 2026, Dannielle Appelhans was elected to Halozyme's Board of Directors.
- Ms. Appelhans was placed in the class of directors with terms ending at the 2028 annual meeting of stockholders.
- She was not initially assigned to any Board committee.
- She will receive compensation under the non-employee director program, which includes cash retainers, restricted stock and stock options.
- The filing states there are no arrangements or understandings tied to her election and no related person transactions.
- The filing contains no financial results, guidance, or other operating information.
03—Questions
Frequently Asked Questions
Who was added to Halozyme's Board of Directors?
Dannielle Appelhans was elected to the Board of Directors on August 14, 2026, as reported in the Form 8-K filed August 18, 2026.
When does Ms. Appelhans's board term expire?
She was elected to the class of directors whose terms end at the Company's annual meeting of stockholders in 2028.
Will Ms. Appelhans serve on any Board committees?
She was not initially assigned to any Board committee.
How will Ms. Appelhans be compensated?
She will receive compensation under the director compensation program for all non-employee directors, as revised from time to time. The filing states that this currently includes cash retainers for Board and committee service, restricted stock and stock option awards. The current program components were described in the proxy statement for the May 5, 2026 annual meeting.
Does the filing disclose any related party arrangements tied to the appointment?
No. The filing states there are no arrangements or understandings pursuant to which Ms. Appelhans was elected, and no related person transactions between the Company and her.
04—Continue